Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biospecimen Procurement for Experimental Transplantation and Immunology Branch Immunotherapy Protocols

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02682667
Recruitment Status : Recruiting
First Posted : February 15, 2016
Last Update Posted : August 19, 2019
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Brief Summary:

Background:

Cancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Researchers want to study samples from people with cancer or a pre-malignant condition. They hope to develop more effective treatments.

Objective:

To better understand the biology of malignancies and why certain cancers respond differently to treatment.

Eligibility:

Adults at least 18 years old with cancer or a pre-cancerous condition.

Design:

Participants will be screened with a medical history, physical exam, and blood tests. Their diagnosis will be confirmed by the NCI Laboratory of Pathology.

Participants will send tissue blocks or slides from their original tumor biopsy.

At least once, participants will have a medical history, physical exam, and blood and urine tests.

Participants may have the following tests. They may have them more than once:

Apheresis. A needle in one arm removes blood. Blood is run through a machine and the sample cells are taken out. The rest of the blood is returned by a needle in the other arm.

Bone marrow aspiration and biopsy. The hipbone will be numbed. A needle will be put into the hipbone. Bone marrow will be taken out through the needle.

Piece of cancer tissue taken by a needle and syringe.

Computed tomography (CT) scan, magnetic resonance imaging (MRI) and/or positron emission tomography (PET) scan or ultrasound to help locate their tumor. For the scans, they lie in a machine that takes pictures.

A small piece of skin removed.

Participants will be contacted by phone once a year to find out how they are doing.


Condition or disease
Multiple Myeloma Lymphoma, Non-Hodgkin Leukemia-Lymphoma, Adult T-Cell Hodgkin Disease Non-Small Cell Lung Cancer

Detailed Description:

Background:

-Immunotherapy is a promising approach to the treatment of cancer. ETIB investigators are studying immunotherapy for the treatment of diverse malignant and premalignant conditions. These studies require the collection of biospecimens for research purposes.

Objectives:

  • To collect and bank blood, apheresis products, tumor, body fluids, and other biospecimens from patients with cancer or a premalignant disease or at risk of cancer from an immunodeficiency.
  • To collect and bank biospecimens as directed by companion ETIB immunotherapy clinical trial protocols.
  • To conduct nucleic acid, protein, and immunological and biological research studies on samples collected.

Eligibility:

-Patients must be 18 years of age or older with a diagnosis of cancer or a premalignant condition or an immunodeficiency that increases the risk of being diagnosed with a cancer or premalignant condition.

Design:

  • Up to 500 subjects will be enrolled.
  • Patients will undergo sampling of blood, apheresis products, tumor, effusions, ascites, urine, bone marrow, serum, plasma, skin, mucosa, or other tissues for banking and laboratory studies.
  • No investigational or experimental therapy will be given as part of this protocol.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Biospecimen Procurement for Experimental Transplantation and Immunology Branch Immunotherapy Protocols
Actual Study Start Date : April 11, 2016
Estimated Primary Completion Date : December 1, 2025
Estimated Study Completion Date : December 1, 2027


Group/Cohort
1/Cohort 1
Patients with cancer or a premalignant condition or at risk of cancer from an immunodeficiency.



Primary Outcome Measures :
  1. Sample Acquisition [ Time Frame: Ongoing ]
    Biospecimen collection for study and understanding of disease.


Secondary Outcome Measures :
  1. Associations between clinical parameters, biospecimen characteristics and patient demographics [ Time Frame: Ongoing ]
    Correlation of these characteristics with disease.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Participants will be any person over the age of 18 with a diagnosis of cancer or a premalignant disease. Participants are selected from other NIH protocols (including screening protocols) they may be co-enrolled on and can include both inpatient and outpatient.
Criteria
  • INCLUSION CRITERIA:

    1. Diagnosis of cancer, a premalignant condition or an immunodeficiency that increases the risk of being diagnosed with a cancer or premalignant condition
    2. Age greater than or equal to 18 years of age
    3. ECOG performance status of 0-3
    4. Ability and willingness of subject to provide informed consent

INCLUSION FOR APHERESIS:

Additional inclusion criteria pertinent only for patients undergoing Apheresis

  1. Hemoglobin greater than or equal to 8 mg/dL and platelet count > 75 K/uLuL
  2. Weight greater than or equal to 48 kg
  3. Central line in place or adequate venous access.

EXCLUSION CRITERIA:

  1. Active concomitant medical or psychological illnesses that may increase the risk to the subject.
  2. Inability to provide informed consent
  3. Pregnant or breastfeeding women (not applicable to patients enrolled only for collection of tissue and blood from outside sources)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02682667


Contacts
Layout table for location contacts
Contact: Erin W Ferraro, R.N. (833) 815-0387 erin.ferraro@nih.gov

Locations
Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937      
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Christian S Hinrichs, M.D. National Cancer Institute (NCI)

Additional Information:
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT02682667     History of Changes
Other Study ID Numbers: 160061
16-C-0061
First Posted: February 15, 2016    Key Record Dates
Last Update Posted: August 19, 2019
Last Verified: August 13, 2019
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):
Apheresis Products
Immunological
Diverse Malignan
Premalignant
Protein
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Multiple Myeloma
Hodgkin Disease
Lymphoma, Non-Hodgkin
Leukemia-Lymphoma, Adult T-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms, Plasma Cell
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Leukemia, T-Cell
Leukemia, Lymphoid
Leukemia